[go: up one dir, main page]

FI20020333A0 - Metyloidun syklodekstriinin uudet kompleksit - Google Patents

Metyloidun syklodekstriinin uudet kompleksit

Info

Publication number
FI20020333A0
FI20020333A0 FI20020333A FI20020333A FI20020333A0 FI 20020333 A0 FI20020333 A0 FI 20020333A0 FI 20020333 A FI20020333 A FI 20020333A FI 20020333 A FI20020333 A FI 20020333A FI 20020333 A0 FI20020333 A0 FI 20020333A0
Authority
FI
Finland
Prior art keywords
cyclodextrin
novel complexes
methylated cyclodextrin
beta
directed
Prior art date
Application number
FI20020333A
Other languages
English (en)
Swedish (sv)
Inventor
Tomi Jaervinen
Janne Mannila
Pekka Jarho
Original Assignee
Tomi Jaervinen
Janne Mannila
Pekka Jarho
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tomi Jaervinen, Janne Mannila, Pekka Jarho filed Critical Tomi Jaervinen
Priority to FI20020333A priority Critical patent/FI20020333A0/fi
Publication of FI20020333A0 publication Critical patent/FI20020333A0/fi
Priority to US10/505,122 priority patent/US7423026B2/en
Priority to CA2476833A priority patent/CA2476833C/en
Priority to AT03702684T priority patent/ATE391138T1/de
Priority to AU2003205807A priority patent/AU2003205807B2/en
Priority to NZ535153A priority patent/NZ535153A/xx
Priority to DE60320088T priority patent/DE60320088T2/de
Priority to EP03702684A priority patent/EP1476472B1/en
Priority to PCT/FI2003/000125 priority patent/WO2003070774A1/en
Priority to ES03702684T priority patent/ES2301780T3/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI20020333A 2002-02-20 2002-02-20 Metyloidun syklodekstriinin uudet kompleksit FI20020333A0 (fi)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FI20020333A FI20020333A0 (fi) 2002-02-20 2002-02-20 Metyloidun syklodekstriinin uudet kompleksit
US10/505,122 US7423026B2 (en) 2002-02-20 2003-02-20 Methylated cyclodextrin complexes
CA2476833A CA2476833C (en) 2002-02-20 2003-02-20 Novel methylated cyclodextrin complexes
AT03702684T ATE391138T1 (de) 2002-02-20 2003-02-20 Neue komplexe methylierter cyclodextrine
AU2003205807A AU2003205807B2 (en) 2002-02-20 2003-02-20 Novel methylated cyclodextrin complexes
NZ535153A NZ535153A (en) 2002-02-20 2003-02-20 Novel methylated cyclodextrin complexes
DE60320088T DE60320088T2 (de) 2002-02-20 2003-02-20 Neue komplexe methylierter cyclodextrine
EP03702684A EP1476472B1 (en) 2002-02-20 2003-02-20 Novel methylated cyclodextrin complexes
PCT/FI2003/000125 WO2003070774A1 (en) 2002-02-20 2003-02-20 Novel methylated cyclodextrin complexes
ES03702684T ES2301780T3 (es) 2002-02-20 2003-02-20 Nuevos complejos de ciclodextrina metilada.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20020333A FI20020333A0 (fi) 2002-02-20 2002-02-20 Metyloidun syklodekstriinin uudet kompleksit

Publications (1)

Publication Number Publication Date
FI20020333A0 true FI20020333A0 (fi) 2002-02-20

Family

ID=8563271

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20020333A FI20020333A0 (fi) 2002-02-20 2002-02-20 Metyloidun syklodekstriinin uudet kompleksit

Country Status (10)

Country Link
US (1) US7423026B2 (fi)
EP (1) EP1476472B1 (fi)
AT (1) ATE391138T1 (fi)
AU (1) AU2003205807B2 (fi)
CA (1) CA2476833C (fi)
DE (1) DE60320088T2 (fi)
ES (1) ES2301780T3 (fi)
FI (1) FI20020333A0 (fi)
NZ (1) NZ535153A (fi)
WO (1) WO2003070774A1 (fi)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110433133A (zh) * 2019-08-19 2019-11-12 中国人民解放军军事科学院军事医学研究院 治疗创伤后应激障碍的大麻二酚鼻用制剂

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI113340B (fi) * 2002-02-20 2004-04-15 Tomi Jaervinen Uudet luonnon syklodekstriinin kompleksit
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
AU2006262195A1 (en) * 2005-06-20 2007-01-04 Unimed Pharmaceuticals, Inc. Dronabinol treatment for migraines
LT2280687T (lt) 2008-03-26 2019-08-26 Stichting Sanammad Kramtomosios gumos kompozicijos, apimančios kanabinoidus
US8735374B2 (en) * 2009-07-31 2014-05-27 Intelgenx Corp. Oral mucoadhesive dosage form
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
TR201815752T4 (tr) 2010-11-25 2018-11-21 Aop Orphan Pharmaceuticals Ag Nabilon ve rastomal metilen beta siklodekstrin içeren hızlı parçalanan bileşimler.
US9744128B2 (en) 2014-06-05 2017-08-29 Mastix LLC Method for manufacturing medicated chewing gum without cooling
EP3442521A4 (en) 2016-04-15 2020-01-01 SRE Wellness, Inc. SWEETENERS AND ELIXIRS INFused WITH CANNABIS
US20220087972A9 (en) 2016-04-15 2022-03-24 Sre Wellness, Inc. Cannabinoid Compositions
JP2019511580A (ja) 2016-04-15 2019-04-25 エスアールイー ウェルネス インク.Sre Wellness Inc. 乳化剤を使用して大麻油を親水性にする方法及び関連するカンナビノイド組成物
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
US10765658B2 (en) 2016-06-22 2020-09-08 Mastix LLC Oral compositions delivering therapeutically effective amounts of cannabinoids
WO2018058235A1 (en) * 2016-09-27 2018-04-05 CannTab Therapeutics Limited Sustained release cannabinoid formulations
US11097206B2 (en) 2016-12-09 2021-08-24 Orochem Technologies Inc. Method for producing purified steviol product using simulated moving bed chromatography
US10058531B1 (en) 2017-06-01 2018-08-28 Spartak LLC Dosage delivery film
SMT202200093T1 (it) 2017-09-28 2022-05-12 Zynerba Pharmaceuticals Inc Trattamento della sindrome dell’x fragile e dell'autismo con cannabidiolo
US11179340B2 (en) * 2017-12-29 2021-11-23 TGC Network LLC Cannabidiol dosage form
CA3088358A1 (en) * 2018-01-13 2019-07-18 Pure Green Pharmaceuticals, Inc. Transformation of cannabinol and terpene oils into water soluble dry powders for solid form sublingual delivery
US20200016091A1 (en) * 2018-07-16 2020-01-16 Orochem Technologies, Inc. Water-soluble cannabidiol
WO2020028897A1 (en) * 2018-08-03 2020-02-06 Lilu's Garden, Ltd. CONSTRUCT OF β-CYCLODEXTRIN AND CANNABINOID GUEST COMPLEX AND PROCESSES FOR PRODUCING A PASTE COMPRISING THE SAME
WO2020121260A1 (en) 2018-12-14 2020-06-18 Zynerba Pharmaceuticals, Inc. Treatment of 22q11.2 deletion syndrome with cannabidiol
US11660283B2 (en) * 2018-12-19 2023-05-30 Joyn Botanicals Ltd. Cannabinoid-containing composition
CN110123876A (zh) * 2019-05-30 2019-08-16 汉义生物科技(北京)有限公司 一种含有非精神活性大麻素的包合物及其制备方法
CN110204426B (zh) * 2019-07-02 2023-05-30 梁志全 一种水溶性cbd的制备方法及水溶性cbd
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
CN115003288A (zh) * 2019-10-21 2022-09-02 埃索拉特有限责任公司 超细化合物及其生产
EP3886837B1 (en) 2019-12-16 2024-02-14 Pisak, Mehmet Nevzat Cannabinoid compositions with high solubility and bioavailabilty
EP4090173A1 (de) * 2020-01-13 2022-11-23 Rrw B.V. Wässrige lösung einer lipophilen verbindung
EP3919046A1 (en) 2020-06-02 2021-12-08 Athenion AG Method for solubilizing natural, endogenous and synthetic cannabinoids
EP4167979A1 (en) * 2020-06-19 2023-04-26 Cannovex BV Pulmonary formulation comprising cannabinoids
CN116782885A (zh) * 2020-07-17 2023-09-19 康纳化学有限责任公司 固体δ9-四氢大麻酚(δ9-thc)组合物
CN114748429A (zh) * 2020-12-29 2022-07-15 汉义生物科技(北京)有限公司 一种水溶性大麻素制剂及其制备方法
WO2024097327A1 (en) * 2022-11-02 2024-05-10 Progressive Therapeutics, Inc. Cannabinoid formulations and use for treatment of emotional disorders and sexual dysfunction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU194858B (en) 1982-12-03 1988-03-28 Chinoin Gyogyszer Es Vegyeszet Process for producing dibenzo/b,d/pirane derivatives and pharmaceutical compositions containing them
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US5180716A (en) * 1990-08-01 1993-01-19 The Regents Of The University Of California Cyclodextrin complexes for neuraxial administration of drugs
GB9726916D0 (en) 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
WO2003033025A2 (en) 2001-10-18 2003-04-24 Decode Genetics Ehf Cyclodextrin complexes
FI113340B (fi) 2002-02-20 2004-04-15 Tomi Jaervinen Uudet luonnon syklodekstriinin kompleksit

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110433133A (zh) * 2019-08-19 2019-11-12 中国人民解放军军事科学院军事医学研究院 治疗创伤后应激障碍的大麻二酚鼻用制剂

Also Published As

Publication number Publication date
AU2003205807A1 (en) 2003-09-09
ATE391138T1 (de) 2008-04-15
CA2476833A1 (en) 2003-08-28
US20050090468A1 (en) 2005-04-28
EP1476472A1 (en) 2004-11-17
AU2003205807B2 (en) 2008-11-20
ES2301780T3 (es) 2008-07-01
US7423026B2 (en) 2008-09-09
WO2003070774A1 (en) 2003-08-28
DE60320088D1 (de) 2008-05-15
EP1476472B1 (en) 2008-04-02
CA2476833C (en) 2011-02-01
DE60320088T2 (de) 2009-06-04
NZ535153A (en) 2006-03-31

Similar Documents

Publication Publication Date Title
FI20020333A0 (fi) Metyloidun syklodekstriinin uudet kompleksit
ATE427763T1 (de) Ballonkatheter
ATE406156T1 (de) Ajulemische säure zur krebsbehandlung
ATE508735T1 (de) Pulmonale verabreichung von aminoglykosiden
BR0308211A (pt) Cumarinas úteis como biomarcadores
EP1551834A4 (en) SUBSTITUTED QUINAZOLINONE COMPOUNDS
MXPA03010134A (es) Derivados de ciclohexan-1-4-diamina sustituidos.
BR0113798A (pt) Derivados de resorcinol
NO20032788D0 (no) Modafinil-forbindelse og cyklodekstrinblandinger
NO20014756D0 (no) C(10)-heterosubstituerte acetattaksaner som antitmormidler
MXPA03008076A (es) Isoflavonas dimericas.
BR0307518A (pt) Composição farmacêutica
EA200200313A1 (ru) Применение доцетаксела для лечения печеночно-клеточного рака
TR200102742T2 (tr) Rezorsinol türevleri
DK1204659T3 (da) Serotonerge benzofuraner
ATE280169T1 (de) Serotonerge benzothiophene
ATE427970T1 (de) Verbesserte mikrogele und filme
ATE402158T1 (de) Flavonoid-derivat
NO20014758L (no) C(7)-heterosubstituerte acetattaxaner som antitumormidler
ATE400285T1 (de) Mischungen von isoflavonen und flavonen
ATE256124T1 (de) Substituierte benzimidazole, ihre herstellung und ihre verwendung als mittel gegen parasitäre protozoen
DE60134814D1 (de) C10-carbamoyloxysubstituierte taxane als antitumormittel
DE60133600D1 (de) C7-carbamoyloxysubstituierte taxane als antitumormittel
ATE432928T1 (de) C10-taxanester als antitumormittel
DE60305964D1 (de) Pyridin-derivate verwendbar als riechstoffe

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: PEDIPHARM OY

Free format text: PEDIPHARM OY